Identification | Back Directory | [Name]
zanamivir hydrate | [CAS]
171094-50-1 | [Synonyms]
ZanaMivir hydrate(5:1) WKZWSOZFPHGMGO-CQGQYZHTSA-N D-glycero-D-galacto-Non-2-enonic acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-, hydrate (5:1) (9CI) | [Molecular Formula]
C60H102N20O36 | [MOL File]
171094-50-1.mol | [Molecular Weight]
1679.56 |
Hazard Information | Back Directory | [Uses]
Zanamivir hydrate (5:1) is the hydrate of Zanamivir. Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively[1]. | [in vivo]
Zanamivir has a poor bioavailability in oral administration, with only 4-17% of the agent. Oral delivery of Zanamivir has been a problem due to its strong hydrophilic nature that limits its transport across the intestinal epithelium. Permeation enhancers such as sodium cholate, hydroxypropyl β-cyclodextrin could be used with zanamivir to enhance the intestinal permeability[3]. | [References]
[1] Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates ofinfluenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8. DOI:10.1128/AAC.45.12.3403-3408.2001 [2] McKimm-Breschkin JL, et al. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4(2):107-16. DOI:10.2165/00151829-200504020-00004 [3] Shanmugam S, et al. Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats. Biomol Ther (Seoul). 2013 Mar;21(2):161-9. DOI:10.4062/biomolther.2013.010 |
|
Company Name: |
SPIRO PHARMA
|
Tel: |
|
Website: |
www.spiropharma.com.cn |
|